GENinCode’s CARDIO inCode-Score® Test Gains New York State Approval

The latest update is out from GENinCode UK Ltd. ( (GB:GENI) ).

GENinCode UK Ltd. has announced the approval of its CARDIO inCode-Score® test by the New York State Department of Health, enabling full state coverage under the US Centers for Medicare and Medicaid Services. This approval allows the company to collect patient samples from New York State for testing at its California lab, marking a significant step in its US market expansion. The test, which predicts genetic risk for heart disease, is expected to enhance preventive healthcare strategies and reduce the economic burden of cardiovascular diseases. The approval also supports GENinCode’s ongoing discussions with the FDA for further market penetration.

The most recent analyst rating on (GB:GENI) stock is a Sell with a £2.00 price target. To see the full list of analyst forecasts on GENinCode UK Ltd. stock, see the GB:GENI Stock Forecast page.

Spark’s Take on GB:GENI Stock

According to Spark, TipRanks’ AI Analyst, GB:GENI is a Underperform.

The overall stock score is heavily influenced by the company’s financial struggles, including persistent losses and negative cash flows. Technical analysis further supports a bearish outlook, with the stock showing weak momentum. Valuation metrics are also unfavorable, with a negative P/E ratio and no dividend yield.

To see Spark’s full report on GB:GENI stock, click here.

More about GENinCode UK Ltd.

GENinCode UK Ltd. is a predictive genetics company based in Oxford, focusing on the prevention of coronary heart disease and the risk assessment of ovarian cancer. The company specializes in genetic risk prediction and prevention strategies, with a market focus on improving public health outcomes related to cardiovascular diseases.

Average Trading Volume: 1,051,233

Technical Sentiment Signal: Strong Sell

Current Market Cap: £6.17M

For detailed information about GENI stock, go to TipRanks’ Stock Analysis page.